Today, many pharmaceutical commercial stocks such as Nanjing Pharmaceutical and Jiashitang rose to the limit

【Pharmaceutical Network Pharmaceutical Stock Market】 On December 5, the pharmaceutical business sector strengthened, Nanjing Pharmaceutical, Jiashitang rose to the limit, Luyan Pharmaceutical, Inter Group, Sinopharm Consistency, Saili Medical, Kaikai Industry, and BAHEAL Pharmaceutical rose to the limit
.
Today, Nanjing Pharmaceutical opened at 5.
71 yuan, and as of 09:49, the stock rose 10.
02% to 6.
15 yuan, closing the rise
.
It is reported that Nanjing Pharmaceutical is mainly engaged in the sales of
pharmaceutical products.
Data show that as of September 30, 2022, Nanjing Pharmaceutical's operating income was 37,436.
17 million yuan, and the net profit attributable to shareholders of the parent company was 470.
24 million yuan, an increase of 35.
779% over last year, and basic earnings per share were 0.
38 yuan
.
In the past month, Nanjing Pharmaceutical has been listed on the Dragon and Tiger List 0 times, indicating that Nanjing Pharmaceutical stocks are inactive
.
According to Nanjing Pharmaceutical's statement on the investor interactive platform on November 22, the company is a regional pharmaceutical commercial enterprise with coordinated development of batch and zero, with more than 600 retail stores (including social retail pharmacies and special pharmacies), and the market network covers Jiangsu, Anhui, Fujian, Hubei and other places and parts of Yunnan
.
At 09:31 on December 05, JiaShitang rose to the limit, and the current transaction was 408 million yuan
.
In terms of data, JiaShitang has a cumulative increase of 33.
12% in the past 3 days, a cumulative increase of 43.
45% in the past 5 days, and a cumulative net inflow of 86 million yuan of main funds in the first 3 days; a cumulative net inflow of 132 million
yuan in the first 5 days.
It is reported that Jiashitang is a pharmaceutical commercial enterprise and a hot stock
of the reform concept of central enterprises.
The data shows that from January to June 2022, the composition of JiaShitang's operating income is: pharmaceutical wholesale (industry) accounted for 91.
94%, pharmaceutical chain (industry) accounted for 6.
89%, and pharmaceutical logistics (industry) accounted for 1.
17%.

In terms of finance, JiaShitang's operating income in the first three quarters of 2022 was 20.
281 billion yuan, a year-on-year increase of 4.
81%.

The net profit attributable to the parent was 247 million yuan, a year-on-year decrease of 6.
96%, and the earnings per share were 0.
85 yuan
.
As of September 30, 2022, the top ten shareholders of Jiashitang held a total of 131 million shares, accounting for 44.
83% of the total share capital, a decrease of 848,900 shares
from the previous period.
At 9:51 on December 5, Luyan Pharmaceutical opened the intraday limit and is now quoted at 10.
63 yuan, with a transaction of 202 million yuan and a turnover rate of 5.
22%.

The stock had previously traded at 9:48 a.
m.

According to Luyan Pharmaceutical's statement on the investor interactive platform on December 1, the company's main business is the distribution of medicines, traditional Chinese medicine pieces, medical devices and pharmaceutical retail chains, and the main source of income is pharmaceutical wholesale sales revenue
.
At 9:57 on December 5, Inter Group opened the intraday limit and is now quoted at 14.
52 yuan, with a transaction of 282 million yuan and a turnover rate of 6.
66%.

The stock previously traded at 9:47 a.
m.

According to Inter Group on the investor interactive platform on November 29, the company is a pharmaceutical circulation enterprise, mainly engaged in the wholesale and retail business of drugs and medical devices in Zhejiang Province, with a wide
range of business categories.
.
.
.
.
.
.
In terms of news, recently, Beijing, Guangzhou and other places have successively adjusted the relevant purchase measures
of "four types of drugs".
The Beijing Municipal Bureau for Market Regulation announced on the evening of December 3 that since December 3, citizens no longer need real-name registration information
to purchase "four types of drugs" such as antipyretic, cough, anti-infection, and treatment of dry throat and sore throat through Internet platforms or pharmacies in the city.
From December 1, Guangzhou pharmacies purchased 37 types of drugs in the "List of Drugs to be Registered and Reporting During the Epidemic", no longer check the negative nucleic acid certificate within 48 hours, just wear a mask, measure the temperature, scan the code, and show the green code of the health code to enter the pharmacy to buy medicines
.
In addition, pharmacies in many places in Hebei Province received a notice from higher-level regulatory authorities on December 1 that pharmacies selling "four types of drugs" would no longer be registered and uploaded
under their real names.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.